Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Cash from Operations (2022 - 2025)

Historic Cash from Operations for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to -$6.5 million.

  • CervoMed's Cash from Operations fell 3317.73% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.9 million, marking a year-over-year decrease of 12621.49%. This contributed to the annual value of -$16.5 million for FY2024, which is 12189.49% down from last year.
  • CervoMed's Cash from Operations amounted to -$6.5 million in Q3 2025, which was down 3317.73% from -$6.5 million recorded in Q2 2025.
  • CervoMed's 5-year Cash from Operations high stood at $6.9 million for Q3 2022, and its period low was -$8.1 million during Q4 2024.
  • Its 4-year average for Cash from Operations is -$2.9 million, with a median of -$2.5 million in 2023.
  • The largest annual percentage gain for CervoMed's Cash from Operations in the last 5 years was 6866.81% (2023), contrasted with its biggest fall of 26654.79% (2023).
  • Quarter analysis of 4 years shows CervoMed's Cash from Operations stood at -$692530.0 in 2022, then tumbled by 266.55% to -$2.5 million in 2023, then tumbled by 217.16% to -$8.1 million in 2024, then increased by 19.7% to -$6.5 million in 2025.
  • Its Cash from Operations stands at -$6.5 million for Q3 2025, versus -$6.5 million for Q2 2025 and -$3.9 million for Q1 2025.